Altimmune, Inc. (NASDAQ:ALT) Receives $16.83 Average PT from Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $16.8333.

A number of brokerages have recently issued reports on ALT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 22nd. Citizens Jmp lowered their target price on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Monday, October 20th. Finally, Citigroup reiterated a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th.

Altimmune Trading Down 3.0%

Shares of NASDAQ:ALT opened at $3.86 on Tuesday. The company has a market capitalization of $402.76 million, a PE ratio of -3.61 and a beta of -0.03. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. Altimmune has a 12-month low of $2.90 and a 12-month high of $8.03. The business’s fifty day simple moving average is $4.52 and its 200-day simple moving average is $4.34.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%.The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, equities research analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In related news, Director John Gill acquired 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average cost of $4.10 per share, with a total value of $51,250.00. Following the transaction, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jerome Benedict Durso bought 12,500 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were bought at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the transaction, the director owned 12,500 shares in the company, valued at $51,625. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sherbrooke Park Advisers LLC purchased a new stake in shares of Altimmune during the third quarter valued at $60,000. Sig Brokerage LP acquired a new stake in Altimmune during the 3rd quarter worth about $130,000. Millennium Management LLC grew its stake in Altimmune by 7,160.7% during the 3rd quarter. Millennium Management LLC now owns 367,582 shares of the company’s stock valued at $1,386,000 after purchasing an additional 372,788 shares during the last quarter. Brevan Howard Capital Management LP increased its holdings in shares of Altimmune by 67.4% in the third quarter. Brevan Howard Capital Management LP now owns 222,942 shares of the company’s stock valued at $840,000 after purchasing an additional 89,733 shares during the period. Finally, Two Sigma Investments LP increased its holdings in shares of Altimmune by 356.6% in the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after purchasing an additional 1,559,562 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.